Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 in healthy volunteers
NCT06746402Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of admilparant (9 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Non-serious Adverse Events, Serious Adverse Events and 7 more. Started Feb 2025; status: completed.
02
Drugs
admilparant
Beyond the preview
Go deeper on NCT06746402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746402.